CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
Aetna, a CVS Health company, has enhanced its Aetna Health app with Spanish language capabilities, making it accessible to all eligible health plan members. The update includes Spanish translations for identity cards, benefit details, deductibles, claims, cost estimates, and healthcare provider information.
The initiative aims to improve navigation, health literacy, and care access for Spanish-speaking members. Aetna also provides Spanish-speaking care managers and customer service representatives, while conducting community outreach through events and broadcast interviews to share public health information in Spanish.
The company plans to explore expanding language capabilities further to serve its diverse member population.
CVS Health has announced the pricing details of its Maximum Tender Offer for multiple series of Senior Notes, with a maximum purchase price of $1,774,423,242.62. The tender offer includes various series of notes with maturities ranging from 2030 to 2050. Notes tendered by the Early Tender Date of December 13, 2024, will receive the Total Consideration, which includes the Early Tender Payment of $30 per $1,000 principal amount.
The settlement date for notes validly tendered by the Early Tender Date is expected to be December 18, 2024. Due to oversubscription at the Early Tender Date, no notes tendered after this date are expected to be accepted for purchase. The 2.700% Senior Notes due 2040, 3.875% Senior Notes due 2047, and 4.250% Senior Notes due 2050 will be accepted at 100% proration, while the 4.125% Senior Notes due 2040 will be accepted at 57.5% proration.
CVS Health announced early results of its cash tender offer for multiple series of senior notes, with a maximum purchase price of $1.77 billion. The tender offer includes ten different series of notes with various interest rates and maturities ranging from 2030 to 2050. As of December 13, 2024, significant portions of various notes have been tendered, with participation rates ranging from 14.56% to 70.61%.
The company will settle the tender offer early on December 18, 2024. The total consideration will be calculated based on U.S. Treasury yields plus fixed spreads, and includes an early tender payment of $30 per $1,000 principal amount. Due to reaching the maximum tender amount, no additional notes will be purchased after the early settlement date.
CVS Health announced the results of its cash tender offer for its 4.100% Senior Notes due 2025. As of December 6, 2024, $225,979,000 in principal amount was validly tendered, with an additional $5,000 tendered under guaranteed delivery procedures. The settlement date is expected to be December 11, 2024.
The company plans to fund the purchase using proceeds from its newly issued 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054. CVS Health expects to accept all validly tendered notes for purchase.
This tender offer is part of a larger initiative that includes a Maximum Tender Offer with a maximum purchase price of $2,000,000,000, less the amount paid for the Any and All Notes.
CVS Health has announced pricing details for its cash tender offer for all outstanding 4.100% Senior Notes due 2025. The total consideration is $998.22 per $1,000 principal amount of notes, with a reference yield of 4.434%. The tender offer expires at 5:00 p.m., New York City time, on December 6, 2024.
The settlement date is expected to be December 11, 2024. Holders will receive accrued and unpaid interest in addition to the total consideration. The offer affects $950,087,000 in outstanding notes. Holders can withdraw tendered notes until the withdrawal deadline of 5:00 p.m., December 6, 2024.
The tender offer is not conditioned on minimum participation but is subject to a financing condition and other general conditions.
CVS Health has announced key leadership appointments in its Pharmacy and Consumer Wellness division. Len Shankman has been named president of Pharmacy and Consumer Wellness (PCW), overseeing front store and retail pharmacy operations across 9,000+ CVS Pharmacy locations. Lucille Accetta has been appointed chief pharmacy officer. Both will report to Prem Shah, group president. The company recently reported positive trends, including a record-high retail pharmacy prescription share of 27.3% and significant progress in transitioning to the CVS CostVantage model, with agreements covering over half of total commercial prescriptions.
CVS Health has announced cash tender offers for certain outstanding notes, including any and all of its 4.100% Senior Notes due 2025 and several other series of notes under a Maximum Tender Offer. The total maximum purchase price across both tenders will not exceed $2 billion. The company plans to fund these purchases using proceeds from a future issuance of subordinated debt securities.
The Any and All Notes tender expires on December 6, 2024, while the Maximum Tender Offer has an Early Tender Date of December 13, 2024, and final expiration on December 31, 2024. The purpose is to retire a portion of CVS Health's outstanding indebtedness.
CVS Health has appointed Dr. Sreekanth Chaguturu as President of Health Care Delivery, while maintaining his current role as Executive Vice President and Chief Medical Officer. He replaces Mike Pykosz, who is leaving the company. The company reported significant growth in its Health Care Delivery business, with Aetna members served by Signify nearly doubling year-over-year and Oak Street's at-risk membership increasing by 32%. The number of Aetna members enrolled at Oak Street has approximately quadrupled since the acquisition. Dr. Chaguturu will focus on connecting care delivery across Oak Street Health clinics, MinuteClinic locations, and Signify Health's home services.
CVS Health has appointed four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. The appointments aim to enhance financial and operational performance through new thinking and industry experience. Norwalk will join the Health Services Committee, Sansone the Audit Committee, and Shulman the Management Planning and Development Committee. The Board now consists of 16 members. CVS Health and Glenview have entered into a confidentiality agreement with customary standstill provisions.
CVS Health (NYSE: CVS) announced that Chief Financial Officer Tom Cowhey will participate in a fireside chat with investors at the Wolfe 2024 Healthcare Conference on November 19, 2024, at approximately 10:20 am ET. The event will be available via audio webcast on the Investor Relations section of the CVS Health website at investors.cvshealth.com, where it will remain accessible for one year.